RU2012148721A - Композиции и способы для лечения обострения хобл - Google Patents
Композиции и способы для лечения обострения хобл Download PDFInfo
- Publication number
- RU2012148721A RU2012148721A RU2012148721/10A RU2012148721A RU2012148721A RU 2012148721 A RU2012148721 A RU 2012148721A RU 2012148721/10 A RU2012148721/10 A RU 2012148721/10A RU 2012148721 A RU2012148721 A RU 2012148721A RU 2012148721 A RU2012148721 A RU 2012148721A
- Authority
- RU
- Russia
- Prior art keywords
- antibody
- copd
- patient
- exacerbation
- inhibits
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract 61
- 239000000203 mixture Substances 0.000 title claims abstract 13
- 239000002699 waste material Substances 0.000 title 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims abstract 29
- 230000005713 exacerbation Effects 0.000 claims abstract 23
- 208000037883 airway inflammation Diseases 0.000 claims abstract 6
- 206010061218 Inflammation Diseases 0.000 claims abstract 5
- 230000004054 inflammatory process Effects 0.000 claims abstract 5
- 210000004072 lung Anatomy 0.000 claims abstract 5
- 210000002345 respiratory system Anatomy 0.000 claims abstract 5
- 238000011285 therapeutic regimen Methods 0.000 claims abstract 5
- 210000000440 neutrophil Anatomy 0.000 claims abstract 4
- 230000011664 signaling Effects 0.000 claims abstract 2
- 208000035143 Bacterial infection Diseases 0.000 claims 4
- 208000036142 Viral infection Diseases 0.000 claims 4
- 208000022362 bacterial infectious disease Diseases 0.000 claims 4
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 claims 4
- 150000003431 steroids Chemical class 0.000 claims 2
- 230000009385 viral infection Effects 0.000 claims 2
- 230000003612 virological effect Effects 0.000 claims 2
- 101001076418 Homo sapiens Interleukin-1 receptor type 1 Proteins 0.000 claims 1
- 101000599048 Homo sapiens Interleukin-6 receptor subunit alpha Proteins 0.000 claims 1
- 102100037792 Interleukin-6 receptor subunit alpha Human genes 0.000 claims 1
- 241001529936 Murinae Species 0.000 claims 1
- 230000000391 smoking effect Effects 0.000 claims 1
- 238000007910 systemic administration Methods 0.000 claims 1
- 230000009885 systemic effect Effects 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2006—IL-1
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Zoology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Pulmonology (AREA)
- Gastroenterology & Hepatology (AREA)
- Endocrinology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US32524110P | 2010-04-16 | 2010-04-16 | |
| US61/325,241 | 2010-04-16 | ||
| US41610210P | 2010-11-22 | 2010-11-22 | |
| US61/416,102 | 2010-11-22 | ||
| PCT/US2011/032910 WO2011130745A1 (en) | 2010-04-16 | 2011-04-18 | Compositions and methods for treating copd exacerbation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2012148721A true RU2012148721A (ru) | 2014-05-27 |
Family
ID=44799068
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2012148721/10A RU2012148721A (ru) | 2010-04-16 | 2011-04-18 | Композиции и способы для лечения обострения хобл |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20130149312A1 (enExample) |
| EP (1) | EP2558112A4 (enExample) |
| JP (1) | JP2013525310A (enExample) |
| KR (1) | KR20130086141A (enExample) |
| CN (1) | CN102985100A (enExample) |
| AU (1) | AU2011239402A1 (enExample) |
| BR (1) | BR112012026545A2 (enExample) |
| CA (1) | CA2796083A1 (enExample) |
| MX (1) | MX2012012063A (enExample) |
| RU (1) | RU2012148721A (enExample) |
| WO (1) | WO2011130745A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104740615A (zh) * | 2013-12-31 | 2015-07-01 | 上海索菲里奥生物医药科技发展有限公司 | IL-1β在制备用于治疗由金黄色葡萄球菌易感所引起的炎症的药物中的用途 |
| WO2015182121A1 (ja) * | 2014-05-29 | 2015-12-03 | 国立研究開発法人医薬基盤・健康・栄養研究所 | アレルギー誘発性物質の検査、アレルギーの診断および治療 |
| WO2016168696A1 (en) * | 2015-04-15 | 2016-10-20 | Ohio State Innovation Foundation | Methods to improve induction of iga antibodies by vaccines |
| WO2016197087A1 (en) | 2015-06-05 | 2016-12-08 | The University Of Rochester | Shape-memory polymers and methods of making and use thereof |
| KR102208549B1 (ko) * | 2019-05-16 | 2021-01-27 | 포항공과대학교 산학협력단 | G-CSF 및 IL-1β를 이용한 호중구성 폐 염증질환의 진단, 예방 또는 치료용 조성물 |
| EP4069847A4 (en) * | 2019-12-02 | 2023-11-15 | Onspira Therapeutics, Inc. | Treatment of lower airways disorders |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2001259758A1 (en) * | 2000-05-12 | 2001-11-26 | Immunex Corporation | Interleukin-1 inhibitors in the treatment of diseases |
| PL377091A1 (pl) * | 2002-09-06 | 2006-01-23 | Amgen, Inc. | Ludzkie monoklonalne przeciwciało przeciw-IL-1R1, o właściwościach terapeutycznych |
| KR20070086896A (ko) * | 2004-12-02 | 2007-08-27 | 도만티스 리미티드 | 항ｉｌ1ｒ1 단일 도메인 항체 및 치료적 용도 |
| JO3058B1 (ar) * | 2005-04-29 | 2017-03-15 | Applied Molecular Evolution Inc | الاجسام المضادة لمضادات -اي ال-6,تركيباتها طرقها واستعمالاتها |
| KR20080077238A (ko) * | 2005-12-01 | 2008-08-21 | 도만티스 리미티드 | 인터루킨 1 수용체 타입 1에 결합하는 비경쟁적 도메인항체 포맷 |
| US8298533B2 (en) * | 2008-11-07 | 2012-10-30 | Medimmune Limited | Antibodies to IL-1R1 |
-
2011
- 2011-04-18 MX MX2012012063A patent/MX2012012063A/es not_active Application Discontinuation
- 2011-04-18 JP JP2013505212A patent/JP2013525310A/ja active Pending
- 2011-04-18 CN CN201180019387XA patent/CN102985100A/zh active Pending
- 2011-04-18 WO PCT/US2011/032910 patent/WO2011130745A1/en not_active Ceased
- 2011-04-18 EP EP11769752.4A patent/EP2558112A4/en not_active Withdrawn
- 2011-04-18 AU AU2011239402A patent/AU2011239402A1/en not_active Abandoned
- 2011-04-18 US US13/641,406 patent/US20130149312A1/en not_active Abandoned
- 2011-04-18 CA CA2796083A patent/CA2796083A1/en not_active Abandoned
- 2011-04-18 BR BR112012026545A patent/BR112012026545A2/pt not_active IP Right Cessation
- 2011-04-18 KR KR1020127030148A patent/KR20130086141A/ko not_active Withdrawn
- 2011-04-18 RU RU2012148721/10A patent/RU2012148721A/ru not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| WO2011130745A1 (en) | 2011-10-20 |
| BR112012026545A2 (pt) | 2019-09-24 |
| CA2796083A1 (en) | 2011-10-20 |
| MX2012012063A (es) | 2013-03-21 |
| EP2558112A4 (en) | 2014-06-18 |
| KR20130086141A (ko) | 2013-07-31 |
| EP2558112A1 (en) | 2013-02-20 |
| JP2013525310A (ja) | 2013-06-20 |
| CN102985100A (zh) | 2013-03-20 |
| AU2011239402A1 (en) | 2012-10-25 |
| US20130149312A1 (en) | 2013-06-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2012148721A (ru) | Композиции и способы для лечения обострения хобл | |
| EA200800905A1 (ru) | Агенты, связывающиеся с мишенью в легочной ткани, для лечения респираторных заболеваний | |
| Shen et al. | The interaction between pulmonary fibrosis and COVID-19 and the application of related anti-fibrotic drugs | |
| KR20230005139A (ko) | 코로나바이러스 감염 및 이로 인한 염증-유발된 폐 손상의 치료 방법 | |
| JP2017507139A5 (enExample) | ||
| JP2006522830A5 (enExample) | ||
| JPWO2021217004A5 (enExample) | ||
| JP2022163050A (ja) | 院内肺炎を予防または治療する方法 | |
| JP2013525310A5 (enExample) | ||
| CN111265662A (zh) | 干预14-3-3在治疗脓毒症中的应用 | |
| US20220363746A1 (en) | Methods for treating coronavirus infection and resulting inflammation-induced lung injury | |
| JP2020504135A5 (enExample) | ||
| JP2007506681A5 (enExample) | ||
| CA3176072A1 (en) | Methods of treating pulmonary injury with cgrp inhibitors | |
| RU2017110093A (ru) | Композиции и способы для профилактики или лечения заболеваний, состояний или процессов, характеризующихся аберрантной пролиферацией фибробластов и накоплением внеклеточного матрикса | |
| CN108339118A (zh) | 治疗或预防阻塞性睡眠呼吸暂停的药物组合物 | |
| US20240317846A1 (en) | Methods for treating coronavirus infection and resulting inflammation-induced lung injury | |
| TWI870471B (zh) | 全身性硬化症治療用醫藥組合物 | |
| US20230272087A1 (en) | Method of treating or preventing acute respiratory distress syndrome | |
| Monteleone et al. | WERE SARS-COV-2 OR ACE-I RESPONSIBLE FOR ANGIOEDEMA OR WAS IT CAUSED BY A SECOND STRIKE? A CASE REPORT. | |
| US10899829B2 (en) | Emapii neutralizing antibody limits influenza A virus (IAV)-induced lung injury | |
| US20230109208A1 (en) | Methods for treating coronavirus infection and resulting inflammation-induced lung injury | |
| KR20250080879A (ko) | 감염성 질환의 치료 또는 예방에 사용하기 위한 혈장과 면역글로불린을 포함하는 조성물 | |
| CN117062609A (zh) | 用于治疗或预防急性呼吸窘迫综合征的方法 | |
| Kahokehr et al. | Glucocorticoids in Perioperative Care |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20150916 |